BioNxt Advances Everolimus ODF with Animal Study

BioNxt Solutions Inc. has announced the progression of its sublingual Everolimus oral dissolvable film (ODF) program. A significant step involves a large-animal pharmacokinetic study in China, comparing two proprietary sublingual formulations with an oral Everolimus product. This study aims to better understand formulation performance, optimizing dosage for future developments.

The primary goal of BioNxt's initiative is to enhance Everolimus delivery for organ transplantation. The current oral form of Everolimus is subject to gastrointestinal absorption and food intake variability. A sublingual approach might offer more consistent delivery and optimized dosing. The ongoing study in beagle dogs will assess these potential advantages through direct absorption and systemic exposure comparisons.

BioNxt's strategy includes exploring further Everolimus applications, such as in oncology, leveraging their experience in sublingual drug delivery systems. Their efforts could provide significant opportunities within the immunosuppressant drug market.